Global Cyclosporine Market, By Indication (Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Others), Route of Administration (Oral, Injectable, Topical), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Cyclosporine Market Analysis and Size
The global cyclosporine market is expected to witness significant growth during the forecast period. According to the World Psoriasis Day consortium, approximately 25 million people worldwide that account for 2 to 3 percent of the total population found to have psoriasis. Cyclosporines have several advantages, such as its capability to prevent organ transplant rejection, and it has increased usage in the medical industry, that is utilized in oral medication to treat inflammation in rheumatoid arthritis. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global cyclosporine market in the forecast period 2022-2029. The expected CAGR of global cyclosporine market is tend to be around 15% in the mentioned forecast period. The market was valued at USD 2 billion in 2021, and it would grow upto USD 6.12 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Cyclosporine is a class of immunosuppressant drugs extensively used in the prevention of organ rejection in transplant patients and in other clinical applications such as arthritis and ophthalmic disorders. The cyclosporine uses their action by reversibly binding to the T-cell receptor and thus inhibit the production of cytokines.
Cyclosporine Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Others), Route of Administration (Oral, Injectable, Topical), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), DAIICHI SANKYO COMPANY, LIMITED (Japan), Apotex Inc (Canada), Mayne Pharma Group Limited (Australia)
|
|
Market Opportunities
|
|
Global Cyclosporine Market Dynamics
Drivers
- Increase in Autoimmune Diseases
As per the National Institute of Environmental Health Sciences, more than 80 autoimmune diseases have been identified namely diabetes (type 1), multiple sclerosis, rheumatoid arthritis, lupus, and celiac disease. Increase in the occurrence of these diseases drives the global cyclosporine drugs market. This boosts the growth of the market.
- Increased Exposure to Smoking and Harmful Substances
The rising drift towards smoking leads to development of many autoimmune disorders such as rheumatoid arthritis. This, in turn, upsurges the demand for cyclosporine drugs. In addition to this, exposure to granite, fine particles of crystalline silica, and other minerals acclerates the risk of developing autoimmune diseases. Many factory labourers who are exposed to these minerals are particularly at a very high risk. This factor increases the demand for cyclosporine drugs and as a result, the market grows.
Opportunities
- Growing Use of Transplant Rejection Prophylaxis
The aspect of transplant rejection prophylaxis is expected to witness heavy growth rate during the forecast period. The increasing adoption of transplantations will further increase the market growth. As per the Health Resources & Services Administration and the U.S. Department of Health and Human Services, around 36,528 transplants were performed in 2018 and around 113,000 people were in high need of transplants as of January 2019. Decline of transplant rejection can be possible through more use of cyclosporine drugs which increase market growth.
- Increased Competitive Strategies
Many major market players are facing strict generic competition, as numerous marketed products have lost patents and a wide variety of cheaper alternatives to branded drugs are available in the market. Several companies are accepting competitive strategies such as regional expansions, new product development, and strategic collaborations for an added advantage. For instance, Teva Pharmaceuticals launched Teva-cyclosporine ophthalmic emulsion in May 2018. It is the first generic version of Restasis in Canada for the treatment of dry eye disease.
Restraints/Challenges
- Side Effects of Cyclosporins
There are several cyclosporins that impose immense side-effects such as high blood pressure, increased hair growth, numbness of hands and feet, headache, diarrhea and many others. This works as a restraint to the market.
- High Cost
The huge expenditure of these cyclosporines surely hamper the market growth.
This global cyclosporine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cyclosporine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Cyclosporine Market Scope
The global cyclosporine market is segmented on the basis of indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Transplant Rejection Prophylaxis
- Rheumatoid Arthritis
- Psoriasis
- Autoimmune Myasthenia Gravis
- Dry Eye
- Others
Route of Administration
- Oral
- Injectable
- Topical
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Cyclosporine Market Regional Analysis/Insights
The global cyclosporine market is analysed and market size insights and trends are provided by indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global cyclosporine market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global cyclosporine market throughout the forecasted period due to the high adoption of cyclosporine drugs, presence of refined healthcare infrastructure and increased patient awareness level as well as high prevalence of ophthalmic disorders.
Asia-Pacific leads the market due to the presence of key generic players in this region and rise in cases of surgeries.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cyclosporine Market Share Analysis
The global cyclosporine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cyclosporine market
Key players operating in the global cyclosporine market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Apotex Inc (Canada)
- Mayne Pharma Group Limited (Australia)
SKU-